SCHEMBL20249303

SCHEMBL20249303

CC(C)(C)c1ccc(N2CC3(CCNCC3)C2)nn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.49
HSD17B10 Q99714 7/20 0.49
CYP1A2 P05177 6/20 0.49
HPGD P15428 4/20 0.49
TSHR P16473 6/20 0.44
PIM1 P11309 2/20 0.40
CYP2D6 P10635 10/20 0.40
USP2 O75604 7/20 0.40
CYP3A4 P08684 6/20 0.40
MAPK1 P28482 3/20 0.40
TP53 P04637 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CYP2C19 P33261 4/20 0.38
CYP2C9 P11712 4/20 0.38
HIF1A Q16665 1/20 0.38
BPTF Q12830 3/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TLR9 Q9NR96 1/20 0.34
TLR8 Q9NR97 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20249295 0.92 ALDH1A1 (0.40) ALDH1A1HSD17B10CYP1A2HPGDTSHR
SCHEMBL20249284 0.85 BPTF (0.33) ALDH1A1HSD17B10CYP1A2HPGDPIM1
SCHEMBL20038231 0.81 CHRNB2 (0.35) BPTF
SCHEMBL18291657 0.80 ALDH1A1 (0.53) ALDH1A1HSD17B10CYP1A2HPGDTSHR
SCHEMBL20249099 0.80 BPTF (0.57) ALDH1A1HSD17B10CYP1A2USP2CYP3A4
SCHEMBL20255557 0.77 ALDH1A1 (0.53) ALDH1A1HSD17B10CYP1A2HPGDTSHR
SCHEMBL18291263 0.77 ALDH1A1 (0.53) ALDH1A1HSD17B10CYP1A2HPGDTSHR
SCHEMBL20249311 0.77 HRH4 (0.33)
SCHEMBL20249270 0.77 TRPV1 (0.30)
SCHEMBL20249244 0.75 TSHR (0.50) ALDH1A1HSD17B10CYP1A2HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 ALDH1A1 944/4885HSD17B10 2513/4885CYP1A2 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.